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Global, regional, and national burden of chronic kidney 
disease, 1990–2017: a systematic analysis for the Global 
Burden of Disease Study 2017
GBD Chronic Kidney Disease Collaboration*
Summary
Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but 
data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, 
regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to 
impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term 
CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the 
term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout.
Methods The main data sources we used were published literature, vital registration systems, end-stage kidney 
disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble 
model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, 
mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was 
used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function.
Findings Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global 
all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was 
no significant change in the age-standardised mortality rate (2·8%, –1·5 to 6·3). In 2017, 697·5 million (95% UI 
649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age 
prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence 
remained stable (1·2%, –1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with 
diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the 
three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, 
and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the 
disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, 
Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-
related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney 
function.
Interpretation Kidney disease has a major effect on global health, both as a direct cause of global morbidity and 
mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and 
deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI.
Funding Bill & Melinda Gates Foundation.
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license.
Introduction
Chronic kidney disease (CKD) is an important 
contributor to morbidity and mortality from non-
communicable diseases, and this disease should be 
actively addressed to meet the UN’s Sustainable 
Development Goal target to reduce premature mortality 
from non-communicable diseases by a third by 2030. 
Treatment costs for CKD rose after the 1960s, with 
availability of renal replacement techniques making 
possible the long-term application of life-saving but 
costly treatment for patients with end-stage kidney 
disease (ESKD).1 The number of people receiving renal 
replacement therapy exceeds 2·5 million and is projected 
to double to 5·4 million by 2030;2 however, in many 
countries, there is a shortage of renal replacement 
services, and an estimated 2·3–7·1 million adults have 
died prematurely from lack of access to this treatment.2 
The effect of CKD also expands well beyond the provision 
of renal replacement services. Large-scale, nationally 
representative screening programmes under taken in the 
2000s in Australia,3 Norway,4 and the USA5 showed that 
more than 10% of the adult population have markers for 
kidney disease. Different research groups have reviewed 
the prevalence of and mortality from CKD in Africa,6 
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Asia,7–10 Australia,3 Europe,11 Latin America,12 North 
America,13 and several geographically dispersed dev el-
oping countries,14 and confirmed the high burden of this 
disease. The primary cause of CKD varies by setting, 
with hypertension and diabetes being the most common 
causes,15 whereas factors such as HIV16 and exposure to 
toxins or heavy metals17 have an additional role in 
developing countries. In some areas of the world with 
especially high burdens of CKD, the cause remains 
unknown.18
CKD has also been recognised as a risk factor for 
cardiovascular disease independent of other conventional 
risk factors for cardiovascular disease.19 CKD is associated 
with an increased risk for cardiovascular disease mortality 
and is a risk multiplier in patients with hypertension and 
diabetes.15,20,21 Importantly, early detection and treatment 
of diabetes, hypertension, and CKD is possible using 
readily available, often inexpensive, treatments. These 
interventions can improve renal and cardiovascular 
outcomes and slow or prevent progression to ESKD.22–24 
Despite the availability of such interventions, the burden 
of CKD and its related risk factors remains under-
studied in many areas of the world. Even in countries 
with available data, disease awareness is low among 
both the general public and health-care authorities.25 As a 
result, many countries have underdeveloped nephrology 
workforces or mainly focus on the provision of treatment 
for ESKD but not for early stages of CKD.
The Global Burden of Disease, Injuries, and Risk 
Factors Study (GBD), with its broad collection of data 
sources and statistical modelling approaches, can deliver 
the most comprehensive estimates of CKD burden to 
date.26–29 We aimed to summarise GBD 2017 findings on 
CKD epidemiology in 195 countries, expressed in terms 
of incidence, prevalence, years lived with disability 
(YLDs), mortality, years of life lost (YLLs), and disability-
adjusted life-years (DALYs). GBD also quantifies the 
burden of health loss due to cardiovascular disease and 
gout that can be attributed to kidney dysfunction. In this 
Article, we use the term CKD to refer to elevated urinary 
albumin:creatinine ratio (ACR), decreased estimated 
glomerular filtration rate (eGFR), dialysis, or kidney 
transplantation as direct causes of morbidity and 
mortality, whereas we use the term impaired kidney 
function to refer to elevated ACR or decreased eGFR 
without dialysis or kidney transplantation as risk factors 
for cardiovascular disease and gout in addition to the 
direct estimates of mortality and morbidity from CKD. 
Most published work is based on one timepoint to define 
elevated ACR or decreased eGFR, excluding the ability 
to examine the full Kidney Disease: Improving Global 
Outcomes (KDIGO) definition of chronicity, which 
Research in context
Evidence before this study
The burden of chronic kidney disease (CKD) is studied 
predominantly in high-income countries, mainly in terms of 
prevalence, quality of life, mortality, and kidney and 
cardiovascular complications. Even where results of large-scale 
national CKD screening programmes are available, many data 
sources report CKD estimates only for selected populations 
(limited by age group, geography, occupation, etc), and for many 
countries there are no data for CKD epidemiology. The Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a 
major effort to collect and incorporate into one system all 
available data for 354 diseases and 84 risk factors from the 
published literature, registries, vital registration systems, verbal 
autopsies, hospital records data, etc. GBD applies comprehensive 
statistical modelling to produce comparable estimates of the 
burden at the global, regional, and national levels.
Added value of this study
We compiled data for CKD epidemiology by doing several 
systematic literature reviews in PubMed and Embase, using 
search queries combining “chronic kidney disease” and 
“prevalence”, and we retrieved publications from 1980 onwards. 
Data related to dialysis and kidney transplantation were 
extracted from annual renal replacement therapy registry 
reports up to 2017 and including the most recent year of 
available data. The results are a variety of estimates of morbidity 
and mortality for CKD as a direct cause of burden, and impaired 
kidney function as a risk factor for cardiovascular disease and 
gout. The statistical modelling approach enabled us to produce 
estimates of kidney disease burden even for countries without 
primary data. We showed a substantial burden of both CKD and 
impaired kidney function at the global level. Prevalence of CKD, 
in particular, is high (9·1% of the global population). Overall, 
CKD and its effect on cardiovascular disease resulted in 
2·6 million (95% uncertainty interval 2·4 to 2·8) deaths and 
35·8 million (33·7 to 38·0) disability-adjusted life-years (DALYs), 
with most DALYs attributable to CKD occurring in middle and 
low-middle Socio-demographic Index (SDI) quintiles. 
Importantly, CKD has continued to rise in rank among leading 
causes of death over the 27-year period studied, because of 
ageing and an increasing burden of risk factors for CKD 
(including diabetes and hypertension) that, together, 
contributed to more than half the deaths from CKD in 2017.
Implications of all the available evidence
The results presented here can help stakeholders form a 
comprehensive action plan to prevent and treat kidney disease. 
These actions should include increasing the awareness of CKD 
among the general public and health-care authorities as well as 
educational programmes for health-care personnel, appropriate 
treatment of risk factors, management of earlier stages of CKD, 
and development of facilities for treating patients with 
end-stage kidney disease. This work could be especially relevant 
for countries in low and middle SDI quintiles, where there is a 
large gap between CKD burden and provision of adequate 
health care.
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includes persistence for at least 3 months. We estimated 
the burden from CKD and the additional burden from 
comorbid cardiovascular disease and gout that can be 
attributed to impaired kidney function. We followed 
the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER; appendix pp 32–33).30
Methods
In GBD, all appropriate data and statistical methods 
are used to borrow strength from predictive covariates 
and geographical proximity to countries with data, so 
estimates can be obtained for countries and years with 
few or no primary data sources. Data collected based on 
different case-definitions or study methods are adjusted 
to the level they would have been at if data were obtained 
using a reference method or case-definition set, for 
each disease or risk factor. Similarly, cause-of-death data 
from vital registrations or verbal autopsy studies are 
adjusted by reassigning deaths coded to less informative 
International Classification of Diseases and Injuries 
(ICD) codes. To account for uncertainty in primary data 
sources, data manipulations, measurement error, and 
the choice of model, all entities quantified in GBD are 
estimated 1000 times over in the ensemble and meta-
regression models, to produce final estimates with 
95% uncertainty intervals (UIs), which comprise the 
2·5th and 97·5th percentiles of the 1000 draws.
Mortality
General methods for processing, standardisation, and 
modelling of cause-of-death data in GBD 2017 are described 
in the appendix (pp 2–5), and are published elsewhere.27 
Briefly, we modelled mortality assigned to diagnostic (ICD) 
codes for CKD using vital registration, verbal autopsy, and 
surveillance system data for 1980–2017. Cause-of-death data 
were mapped to GBD categories based on ICD-9 and 
ICD-10 codes (appendix p 12). Aggregated data were age–
sex split, and intermediate or poorly defined ICD codes 
were redistributed to a more appropriate GBD cause using 
regression or proportional redistribution methods.27 Most 
codes redistributed to CKD belonged to hypertension, 
unspecified anaemia, and heart failure.
We used the GBD Cause of Death Ensemble model 
(CODEm) process to produce estimates of mortality due 
to CKD. CODEm fits mixed-effects and spatiotemporal 
Gaussian process regression models using predictive 
covariates to estimate either the fraction of total deaths 
due to CKD (cause fraction) or mortality rates by location, 
year, age, and sex from 1980 to 2017. The final model is 
a weighted average of submodels, with weights assigned 
based on out-of-sample predictive validity. Cause fractions 
from CODEm models were multiplied by GBD all-cause 
mortality estimates to approximate the number of deaths 
and mortality rate due to CKD. We scaled CODEm results 
for all causes to be consistent with all-cause mortality 
estimates by country, year, age, and sex.
Non-fatal estimation
We defined prevalent CKD as an abnormality of kidney 
function, indicated by low eGFR based on serum creati-
nine measurement, elevated ACR, or both. We modelled 
six categories of prevalent CKD, defined by level of eGFR 
and ACR or renal replacement therapy. The categories 
defined in GBD are CKD stages 1–2, stage 3, stage 4, and 
stage 5, ESKD on maintenance dialysis, and kidney 
transplant ation. The GBD definition of CKD differs from 
that presented in the KDIGO 2012 Clinical Practice 
Guidelines,22 because the GBD definition uses only one 
measurement of eGFR and ACR and, thus, does not 
formally fit the KDIGO duration requirement of abnor-
malities for more than 3 months. The GBD definition also 
does not take into account markers of kidney damage 
other than ACR, since these are often not reported in 
epidemiological studies used to estimate disease occur-
rence. The criteria used to define CKD categories in GBD, 
and how these entities correspond with KDIGO guidelines, 
are presented in table 1.
Building on past data collection efforts for GBD,31 we 
updated the systematic review of the literature for 
cross-sectional or cohort studies reporting population-
representative prevalence of each stage of CKD based on 
serum creatinine measurements or eGFR and ACR 
values. New data for dialysis and transplantation were 
largely obtained from national registries for ESKD. 
We included 216 unique data sources for the prevalence 
of CKD stages 1–2, stage 3, stage 4, and stage 5 and 
193 sources of data for incidence and prevalence of renal 
replacement therapy. A full list of sources used in the 
See Online for appendix
Definition KDIGO category
CKD stages 1 and 2 eGFR ≥60 mL/min per 1·73 m² and ACR ≥30 mg/g (not including kidney 
transplant recipients)
G1–G2, A2–A3 (not including kidney transplant recipients)
CKD stage 3 eGFR 30–59 mL/min per 1·73 m² (not including kidney transplant recipients) G3a–G3b, A1–A3 (not including kidney transplant recipients)
CKD stage 4 eGFR 15–29 mL/min per 1·73 m² (not including kidney transplant recipients) G4, A1–A3 (not including kidney transplant recipients)
CKD stage 5 eGFR <15 mL/min per 1·73 m² (not including kidney transplant recipients or 
patients treated by dialysis)
G5, A1–A3 (not including kidney transplant recipients or patients treated by dialysis)
ESKD Kidney transplant recipients and patients treated by dialysis Not applicable (classified according to G category, with use of a D or T modifier)
CKD=chronic kidney disease. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. KDIGO=Kidney Disease: Improving Global Outcomes. eGFR=estimated glomerular filtration rate. ACR=albumin:creatinine 
ratio. ESKD=end-stage kidney disease. G=glomerular filtration rate. A=albuminuria. D=dialysis. T=transplant.
Table 1: CKD staging definitions in the GBD study and correspondence with KDIGO categories
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CKD non-fatal estimation process is available through the 
Global Health Data Exchange.
We modelled each stage of CKD separately in 
DisMod-MR 2.1, which is a Bayesian mixed-effects meta-
regression tool developed specifically for GBD by the 
Institute for Health Metrics and Evaluation (Seattle, WA, 
USA). DisMod uses input data for several epidemiological 
parameters, including prevalence, incidence, remission 
rate, and excess mortality rate, to make consistent 
estimates of each parameter. We also ran a DisMod-MR 2.1 
model for the prevalence of CKD stages 3–5 combined 
and scaled estimates for the prevalence of CKD stage 3, 
stage 4, and stage 5 to sum to the prevalence of stages 3–5 
combined for each country–year–age–sex group.
The Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation was designated as the reference 
equation for estimating GFR in adults aged 18 years and 
older.32 We adjusted data reporting eGFR with the 
Modification of Diet in Renal Disease (MDRD) formula by 
a fixed ratio to the level of data reporting prevalence with 
the CKD-EPI equation.33 The CKD stages 1–2 model 
included fixed-effects to adjust input data using alternate 
ACR thresholds (17 mg/g, 20 mg/g, or 25 mg/g) to define 
elevated urinary ACR. Studies using dipstick tests to assess 
proteinuria were not used.
CKD is one of the causes of anaemia estimated in 
GBD. Anaemia prevalence was approximated for all 
causes combined and then attributed to underlying 
causes. Methods related to the cause-specific attribu-
tion of anaemia prevalence have been described 
elsewhere.26,34
Estimates of CKD by cause
We estimated the burden of CKD for each of five causes: 
type 1 diabetes, type 2 diabetes, glomerulonephritis, 
hypertension, and a residual category of other and 
unspecified causes. For CKD stages 1–2, stage 3, stage 4, 
and stage 5, we estimated stage-specific distributions of 
causes. We used available laboratory and ICD-coded 
diagnosis data from Geisinger Health System,35 a health 
maintenance organisation in central and northern 
Pennsylvania, to identify patients with CKD stages 1–2, 
stage 3, stage 4, or stage 5 not on renal replacement 
therapy. For every individual with CKD, we used ICD 
codes for primary renal diseases to map individuals to 
GBD cause groupings (appendix p 12). Individuals with 
CKD but no ICD code for a primary renal disease were 
classified as having CKD of uncertain cause. We ran a 
multinomial logistic regression including sex and a 
non-linear term for age to predict the probability of each 
cause by age and sex for each stage of CKD.
We used data from ESKD registries to model the 
proportion of ESKD and CKD mortality attributable 
to each cause. Registry data were extracted to represent 
the proportion of cases of ESKD attributable to each 
modelled cause of CKD, excluding cases with unknown 
or missing cause. We ran a DisMod-MR 2.1 model for 
each cause. Results from the five cause proportion 
models were then scaled to sum to 1 for each country–
year–age–sex and applied to CKD cause-of-death data 
and ESKD prevalence and incidence estimates.
DALY estimation
We multiplied estimates of deaths due to CKD by 
estimates of standard life expectancy by age, to produce 
estimates of YLLs for CKD.27 Non-fatal CKD estimates 
were separated into 15 unique sequelae dependent on 
CKD stage and anaemia severity (appendix pp 6–13). 
We calculated YLDs for each CKD sequela, multiplying 
the prevalence of each sequela by its corresponding 
disability weight.26 We summed YLDs and YLLs for 
each CKD cause to estimate DALYs. We quantified 
uncertainty around all estimates by taking 1000 draws 
from the distributions of sampling error, residual error, 
and corrections for measurement error. Inherent to the 
CODEm methods is the additional uncertainty from 
model choice. Final 95% UIs were calculated.
Socio-demographic Index
Socio-demographic Index (SDI) is a summary measure of 
development, created as a composite of a country’s total 
fertility rate for women younger than 25 years, educational 
attainment, and lag-distributed income per capita. 
Methods of SDI development and computation are 
detailed elsewhere.36 The expected relation between SDI 
and DALY rates was determined by fitting a Gaussian 
process regression on estimates for all locations from 
1980 to 2017.
Risk estimation
We estimated the burden of CKD stages 1–2, stage 3, 
stage 4, and stage 5 not including renal replacement 
therapy, termed impaired kidney function (table 1), as 
a risk factor for ischaemic heart disease, stroke, 
peripheral vascular disease, and gout. For the estimation 
of risk factors in GBD we use a counterfactual approach 
rather than the categorical assignment to causes. 
One cannot categorically assign a case or death from 
ischaemic heart disease to impaired kidney function 
while there is evidence for an elevated risk of ischaemic 
heart disease in the presence of impaired kidney 
function. In the counterfactual approach we answer the 
question, what would the number of cases or deaths of 
ischaemic heart disease have been if no one in the 
population had impaired kidney function? The difference 
between the counterfactual and observed levels of 
ischaemic heart disease is what is being attributed to the 
risk factor. To capture the full range of health loss 
resulting from decreased eGFR and elevated ACR, we 
also attributed 100% of CKD prevalence to impaired 
kidney function, such that all CKD burden was also 
considered as burden attributable to impaired kidney 
function exposure. We set the theoretical minimum risk 
exposure level (TMREL) at an ACR of 30 mg/g or lower 
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
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Prevalence (95% UI) Deaths (95% UI)
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
Global 697 509 472 
(649 209 403 to 752 050 655)
8724  
(8124 to 9403)
1·2%  
(–1·1 to 3·5)
1 230 168  
(1 195 114 to 1 258 829)
15·9  
(15·5 to 16·3)
2·8%  
(–1·5 to 6·3)
Low SDI 77 774 182  
(72 385 752 to 84 063 152)
9216  
(8586 to 9953)
3·5%  
(0·5 to 7·1)
129 592  
(122 760 to 148 511)
19·6  
(18·5 to 22·5)
–18·7%  
(–24·3 to –11·5)
Low-middle SDI 130 543 398 
(121 443 210 to 140 950 835)
9699  
(9026 to 10 459)
4·8%  
(2·2 to 7·6)
264 227  
(248 849 to 277 138)
23·6  
(22·2 to 24·7)
–4·7%  
(–11·4 to 1·9)
Middle SDI 200 995 222 
(186 451 768 to 216 402 786)
8921  
(8299 to 9622)
2·9%  
(0·7 to 4·9)
415 257  
(387 925 to 426 580)
20·3  
(19·0 to 20·8)
6·6%  
(–0·3 to 10·7)
High-middle SDI 158 186 168 
(147 025 105 to 170 499 238)
9093  
(8464 to 9784)
–4·6%  
(–6·7 to –2·4)
173 695  
(168 779 to 178 805)
10·4  
(10·1 to 10·7)
–7·9%  
(–12·9 to –4·4)
High SDI 127 352 466 
(118 614 944 to 137 500 134)
6804  
(6340 to 7331)
–4·4%  
(–7·3 to –1·8)
243 425  
(238 219 to 249 279)
9·5  
(9·3 to 9·7)
4·1%  
(2·0 to 6·4)
East Asia 139 556 765  
(128 479 977 to 151 557 920)
7201  
(6677 to 7766)
–5·9%  
(–7·9 to –4·1)
189 323  
(174 072 to 197 062)
10·2  
(9·4 to 10·6)
–17·9%  
(–28·7 to –12·6)
China 132 324 202  
(121 756 611 to 143 737 211)
7180  
(6658 to 7747)
–6·1%  
(–8·1 to –4·3)
175 891  
(160 601 to 183 366)
10·0  
(9·2 to 10·4)
–19·0%  
(–30·2 to –13·6)
North Korea 2 233 310  
(2 069 070 to 2 414 053)
7300  
(6796 to 7885)
2·5%  
(–0·2 to 5·4)
3639  
(3088 to 4240)
12·3  
(10·4 to 14·3)
10·3%  
(–9·6 to 36·8)
Taiwan (province of 
China)
2 751 072  
(2 552 629 to 2 961 715)
8145  
(7557 to 8770)
–4·9%  
(–8·0 to –1·7)
6743  
(6319 to 7164)
17·4  
(16·3 to 18·5)
–15·5%  
(–21·9 to –8·8)
Southeast Asia 69 598 036  
(64 285 483 to 75 118 675)
10 802  
(10 029 to 11 635)
6·0%  
(3·8 to 8·3)
134 459  
(127 712 to 142 283)
24·5  
(23·3 to 25·8)
–4·3%  
(–9·8 to 2·1)
Cambodia 1 262 506  
(1 165 067 to 1 366 871)
9580  
(8872 to 10 366)
1·7%  
(–2·0 to 5·7)
1838  
(1621 to 2097)
17·1  
(15·3 to 19·5)
–33·3%  
(–43·4 to –21·5)
Indonesia 27 232 922  
(25 084 990 to 29 398 099)
11 164  
(10 372 to 12 008)
7·6%  
(5·5 to 10·0)
35 446  
(33 322 to 38 551)
17·3  
(16·2 to 19·3)
–16·5%  
(–23·8 to –8·9)
Laos 573 411  
(529 796 to 620 592)
10 781  
(10 001 to 11 628)
1·9%  
(–1·3 to 5·2)
1046  
(881 to 1211)
24·8  
(21·3 to 28·6)
–38·8%  
(–49·9 to –26·0)
Malaysia 3 187 367  
(2 920 099 to 3 476 760)
11 079  
(10 178 to 12 020)
9·7%  
(5·9 to 13·8)
4731  
(4285 to 5249)
21·1  
(19·1 to 23·2)
–3·6%  
(–15·0 to 13·5)
Maldives 41 258  
(37 840 to 44 813)
10 021  
(9311 to 10 796)
–8·0%  
(–10·8 to –5·2)
68  
(62 to 75)
25·5  
(23·1 to 28·1)
–54·8%  
(–61·2 to –47·8)
Mauritius 218 092  
(201 865 to 235 917)
13 768  
(12 789 to 14 903)
19·1%  
(14·1 to 24·1)
1070  
(978 to 1158)
67·0  
(61·4 to 72·3)
54·4%  
(39·1 to 68·8)
Myanmar 5 258 275  
(4 859 659 to 5 677 295)
10 658  
(9909 to 11 506)
2·6%  
(–0·5 to 5·4)
12 026  
(10 523 to 13 747)
28·4  
(25·0 to 32·5)
–31·9%  
(–44·8 to –16·5)
Philippines 9 317 802  
(8 615 652 to 10 028 481)
11 049  
(10 263 to 11 879)
13·2%  
(10·2 to 16·1)
34 051  
(30 042 to 38 555)
50·3  
(44·5 to 56·4)
108·9%  
(83·0 to 137·8)
Sri Lanka 2 745 171  
(2 543 226 to 2 967 595)
11 428  
(10 612 to 12 348)
15·9%  
(12·3 to 19·4)
4512  
(3727 to 5288)
19·9  
(16·7 to 23·1)
–17·0%  
(–30·9 to –1·9)
Seychelles 12 354  
(11 436 to 13 289)
11 094  
(10 330 to 11 897)
3·5%  
(0·8 to 6·4)
41  
(38 to 45)
41·4  
(38·0 to 44·7)
24·4%  
(9·1 to 38·6)
Thailand 9 560 638  
(8 760 453 to 10 414 024)
10 292  
(9461 to 11 174)
–3·9%  
(–7·2 to –0·3)
21 922  
(19 297 to 24 420)
23·3  
(20·5 to 25·9)
–12·6%  
(–23·6 to –0·7)
Timor-Leste 93 556  
(86 875 to 101 038)
10 362  
(9623 to 11 208)
3·6%  
(0·4 to 7·1)
147  
(121 to 175)
19·4  
(16·3 to 22·8)
–26·1%  
(–39·9 to –9·8)
Vietnam 10 003 107  
(9 262 628 to 10 787 589)
10 107  
(9407 to 10 887)
5·4%  
(1·9 to 9·1)
17 384  
(15 393 to 19 609)
20·6  
(18·2 to 23·0)
–20·2%  
(–32·6 to –5·0)
Oceania 1 097 010  
(1 007 760 to 1 187 872)
12 329  
(11 465 to 13 266)
9·0%  
(6·5 to 11·4)
2900  
(2500 to 3318)
45·2  
(40·0 to 50·0)
22·3%  
(2·9 to 39·3)
American Samoa 6328  
(5837 to 6843)
13 217  
(12 268 to 14 234)
11·1%  
(8·0 to 14·4)
24  
(21 to 26)
64·6  
(57·2 to 71·3)
58·5%  
(27·2 to 83·5)
Federated States of 
Micronesia
10 839  
(10 011 to 11 776)
12 990  
(12 071 to 14 015)
13·5%  
(10·4 to 16·7)
39  
(31 to 46)
62·6  
(51·3 to 72·9)
42·6%  
(12·9 to 74·3)
Fiji 119 629  
(110 015 to 129 696)
14 399  
(13 355 to 15 577)
8·8%  
(6·0 to 12·0)
278  
(243 to 316)
44·7  
(39·2 to 50·3)
32·2%  
(4·9 to 60·0)
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Guam 21 526  
(19 937 to 23 259)
12 252  
(11 374 to 13 220)
14·3%  
(11·2 to 17·4)
60  
(53 to 66)
35·5  
(31·2 to 38·9)
82·0%  
(45·3 to 108·7)
Kiribati 11 496  
(10 579 to 12 475)
13 285  
(12 293 to 14 311)
9·0%  
(6·0 to 12·1)
28  
(22 to 32)
42·5  
(34·5 to 48·9)
29·1%  
(–0·8 to 53·1)
Marshall Islands 5295  
(4861 to 5739)
12 311  
(11 398 to 13 279)
8·5%  
(5·6 to 11·2)
20  
(16 to 23)
65·4  
(54·8 to 75·6)
25·6%  
(5·6 to 46·3)
Northern Mariana 
Islands
6379  
(5849 to 6965)
12 283  
(11 407 to 13 247)
9·9%  
(7·2 to 12·8)
18  
(16 to 20)
43·3  
(38·6 to 48·3)
22·2%  
(2·0 to 45·8)
Papua New Guinea 745 077  
(682 404 to 809 149)
11 936  
(11 088 to 12 856)
10·0%  
(6·8 to 13·0)
1964  
(1605 to 2356)
42·5  
(35·7 to 49·6)
18·3%  
(–3·2 to 41·0)
Samoa 19 031  
(17 609 to 20 486)
12 455  
(11 562 to 13 418)
10·5%  
(7·8 to 13·2)
56  
(48 to 65)
46·6  
(39·5 to 53·2)
47·3%  
(20·0 to 78·4)
Solomon Islands 53 882  
(49 662 to 58 673)
12 402  
(11 496 to 13 391)
10·9%  
(8·0 to 13·5)
149  
(129 to 173)
43·0  
(38·0 to 48·8)
6·9%  
(–14·9 to 32·9)
Tonga 11 679  
(10 801 to 12 621)
13 491  
(12 508 to 14 570)
10·0%  
(7·1 to 13·0)
38  
(31 to 45)
50·9  
(41·8 to 59·6)
38·7%  
(11·8 to 63·6)
Vanuatu 25 397  
(23 508 to 27 562)
12 378  
(11 488 to 13 336)
12·6%  
(10·0 to 15·6)
67  
(51 to 85)
43·5  
(34·2 to 53·6)
37·4%  
(5·9 to 76·5)
Central Asia 8 648 124  
(8 016 509 to 9 331 529)
10 604  
(9867 to 11 401)
7·5%  
(5·5 to 9·4)
9506  
(9049 to 10 015)
13·1  
(12·5 to 13·8)
60·9%  
(53·3 to 68·9)
Armenia 434 331  
(403 778 to 468 881)
11 302  
(10 521 to 12 145)
10·7%  
(6·3 to 15·9)
430  
(407 to 452)
10·6  
(10·1 to 11·1)
67·8%  
(56·2 to 80·7)
Azerbaijan 1 101 700  
(1 015 266 to 1 187 536)
10 937  
(10 133 to 11 809)
8·9%  
(6·0 to 12·0)
1169  
(1024 to 1298)
14·2  
(12·2 to 15·7)
83·4%  
(50·9 to 108·2)
Georgia 559 200  
(519 403 to 604 881)
10 810  
(10 028 to 11 660)
12·1%  
(7·6 to 16·8)
785  
(732 to 834)
13·6  
(12·7 to 14·4)
128·5%  
(111·7 to 147·0)
Kazakhstan 1 774 266  
(1 642 487 to 1 917 077)
10 093  
(9350 to 10 878)
1·2%  
(–1·3 to 3·7)
1485  
(1394 to 1585)
9·3  
(8·7 to 9·9)
35·2%  
(26·8 to 44·3)
Kyrgyzstan 482 340  
(447 058 to 520 716)
9482  
(8822 to 10 237)
–0·5%  
(–3·9 to 2·9)
451  
(422 to 483)
9·1  
(8·6 to 9·8)
15·4%  
(6·6 to 24·6)
Mongolia 269 339  
(248 417 to 290 867)
10 050  
(9331 to 10 833)
–7·1%  
(–10·5 to –3·5)
328  
(294 to 391)
15·3  
(13·8 to 17·3)
–62·1%  
(–67·1 to –49·0)
Tajikistan 656 378  
(609 283 to 709 617)
10 093  
(9403 to 10 903)
1·8%  
(–1·7 to 5·7)
641  
(569 to 701)
11·2  
(9·8 to 12·3)
17·2%  
(2·3 to 29·6)
Turkmenistan 473 830  
(438 811 to 510 957)
10 949  
(10 200 to 11 786)
8·8%  
(5·7 to 11·7)
632  
(588 to 681)
16·0  
(14·9 to 17·2)
76·1%  
(62·2 to 91·5)
Uzbekistan 2 896 741  
(2 684 400 to 3 127 941)
10 993  
(10 244 to 11 818)
14·2%  
(10·7 to 17·5)
3584  
(3184 to 4020)
15·9  
(14·3 to 17·7)
104·5%  
(81·3 to 128·4)
Central Europe 13 951 402  
(12 930 450 to 15 136 020)
7659  
(7115 to 8282)
–2·7%  
(–6·2 to 1·4)
16 284  
(15 806 to 16 706)
7·5  
(7·3 to 7·7)
–21·2%  
(–23·6 to –18·9)
Albania 272 017  
(251 454 to 295 588)
7259  
(6756 to 7864)
–1·1%  
(–5·2 to 3·1)
363  
(302 to 447)
9·2  
(7·7 to 11·2)
–17·2%  
(–30·2 to –1·4)
Bosnia and Herzegovina 427 229  
(394 850 to 464 061)
8273  
(7655 to 8943)
5·9%  
(1·3 to 10·4)
604  
(550 to 662)
10·5  
(9·6 to 11·5)
–0·4%  
(–10·1 to 9·9)
Bulgaria 981 339 
(909 610 to 1 061 687)
8000  
(7420 to 8630)
2·6%  
(–0·7 to 5·9)
1447  
(1346 to 1557)
10·1  
(9·4 to 10·8)
45·7%  
(35·3 to 57·2)
Croatia 562 778  
(520 865 to 610 153)
7779  
(7206 to 8390)
1·2%  
(–3·1 to 6·2)
829  
(776 to 888)
8·8  
(8·2 to 9·4)
35·3%  
(25·6 to 46·0)
Czech Republic 1 378 623  
(1 278 611 to 1 497 741)
7998  
(7442 to 8628)
–2·5%  
(–7·0 to 2·8)
1257  
(1173 to 1348)
5·9  
(5·5 to 6·4)
–28·4%  
(–33·6 to –22·4)
Hungary 1 323 316  
(1 226 092 to 1 433 403)
8204  
(7596 to 8881)
1·0%  
(–2·4 to 4·5)
1553  
(1457 to 1646)
7·6  
(7·2 to 8·1)
34·4%  
(26·2 to 44·1)
Montenegro 71 678  
(66 286 to 77 704)
8118  
(7528 to 8773)
–1·5%  
(–5·0 to 2·4)
127  
(113 to 141)
13·1  
(11·7 to 14·5)
–1·2%  
(–12·3 to 11·0)
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North Macedonia 253 249  
(235 058 to 274 801)
8308  
(7720 to 8982)
2·4%  
(–1·7 to 6·9)
309  
(280 to 341)
9·4  
(8·5 to 10·3)
–11·3%  
(–20·5 to –0·8)
Poland 4 335 349  
(3 981 687 to 4 770 568)
7271  
(6702 to 7943)
–6·0%  
(–12·9 to 0·9)
3442  
(3238 to 3669)
4·8  
(4·5 to 5·1)
–50·1%  
(–53·5 to –46·2)
Romania 2 313 736  
(2 124 485 to 2 516 663)
7292  
(6716 to 7930)
–4·9%  
(–7·9 to –1·9)
3043  
(2852 to 3223)
8·0  
(7·6 to 8·5)
–34·1%  
(–38·5 to –29·7)
Serbia 1 142 513  
(1 063 208 to 1 237 929)
8421  
(7846 to 9069)
–0·5%  
(–4·1 to 3·3)
2386  
(1982 to 2607)
14·8  
(12·4 to 16·1)
18·8%  
(7·3 to 32·0)
Slovakia 623 048  
(576 652 to 676 236)
7736  
(7188 to 8341)
–3·1%  
(–7·2 to 1·3)
713  
(653 to 775)
8·1  
(7·4 to 8·8)
–34·9%  
(–41·5 to –27·6)
Slovenia 266 527  
(247 205 to 289 578)
7581  
(7056 to 8179)
–1·1%  
(–5·7 to 3·2)
213  
(195 to 232)
4·4  
(4·0 to 4·8)
–30·2%  
(–36·7 to –23·1)
Eastern Europe 38 150 170  
(35 346 449 to 41 409 966)
12 408  
(11 509 to 13 389)
3·0%  
(0·1 to 6·5)
15 734  
(15 390 to 16 112)
4·8  
(4·7 to 4·9)
–11·2%  
(–13·3 to –9·0)
Belarus 1 558 671  
(1 440 559 to 1 695 898)
11 089  
(10 287 to 12 028)
–1·6%  
(–6·6 to 4·7)
485  
(451 to 525)
3·1  
(2·9 to 3·3)
–32·7%  
(–37·4 to –27·1)
Estonia 258 859  
(240 037 to 279 019)
12 058  
(11 180 to 13 022)
3·6%  
(0·7 to 6·5)
268  
(237 to 303)
8·9  
(7·9 to 10·1)
156·9%  
(124·7 to 194·1)
Latvia 386 621  
(358 442 to 419 031)
11 899  
(11 041 to 12 884)
5·3%  
(0·8 to 9·6)
259  
(232 to 291)
6·2  
(5·5 to 6·9)
41·5%  
(25·5 to 59·6)
Lithuania 533 970  
(494 198 to 578 929)
11 328  
(10 507 to 12 282)
1·1%  
(–2·9 to 5·7)
253  
(235 to 270)
4·3  
(4·0 to 4·6)
–6·1%  
(–13·5 to 1·8)
Moldova 587 124  
(542 018 to 635 358)
11 355  
(10 494 to 12 260)
1·2%  
(–2·1 to 5·4)
207  
(196 to 219)
3·8  
(3·6 to 4·0)
–3·7%  
(–9·7 to 3·2)
Russia 26 981 655  
(24 997 909 to 29 311 266)
12 832  
(11 918 to 13 878)
4·5%  
(1·4 to 8·1)
11 361  
(11 135 to 11 621)
5·1  
(5·0 to 5·2)
–14·7%  
(–16·8 to –12·7)
Ukraine 7 843 270  
(7 253 666 to 8 469 940)
11 571  
(10 707 to 12 495)
–1·6%  
(–4·8 to 2·1)
2900  
(2750 to 3066)
4·1  
(3·8 to 4·3)
–4·3%  
(–9·6 to 1·9)
High-income Asia-
Pacific
27 550 513  
(25 730 339 to 29 608 610)
8098  
(7569 to 8699)
–7·5%  
(–10·3 to –5·2)
42 468  
(40 550 to 45 192)
7·6  
(7·3 to 8·1)
–41·1%  
(–43·5 to –37·6)
Brunei 40 907  
(37 231 to 44 776)
10 323  
(9524 to 11 169)
–8·7%  
(–11·5 to –5·7)
70  
(64 to 77)
26·0  
(23·7 to 28·6)
–13·2%  
(–27·1 to 0·2)
Japan 21 411 356  
(19 946 798 to 23 210 020)
8404  
(7838 to 9068)
–5·9%  
(–8·6 to –3·3)
35 709  
(33 921 to 38 263)
7·5  
(7·1 to 8·0)
–40·3%  
(–43·0 to –36·3)
South Korea 5 451 810  
(5 023 911 to 5 877 265)
7103  
(6560 to 7659)
–9·2%  
(–14·5 to –5·6)
6095  
(5630 to 6562)
7·7  
(7·1 to 8·2)
–40·6%  
(–45·8 to –35·1)
Singapore 646 440  
(598 329 to 700 408)
9333  
(8659 to 10 090)
–8·8%  
(–10·9 to –6·6)
594  
(555 to 639)
9·0  
(8·4 to 9·7)
–36·7%  
(–41·5 to –31·4)
Australasia 2 919 853  
(2 708 028 to 3 164 634)
6964  
(6471 to 7518)
–0·7%  
(–4·5 to 3·3)
5228  
(4833 to 5656)
9·2  
(8·5 to 10·0)
8·8%  
(–0·7 to 18·8)
Australia 2 471 845  
(2 295 264 to 2 676 433)
6982  
(6497 to 7530)
–0·9%  
(–4·7 to 3·3)
4455  
(4068 to 4886)
9·2  
(8·3 to 10·1)
6·1%  
(–4·8 to 17·6)
New Zealand 448 008  
(415 420 to 484 747)
6859  
(6375 to 7436)
0·2%  
(–4·0 to 4·9)
773  
(732 to 819)
9·4  
(8·9 to 10·0)
21·6%  
(13·5 to 29·8)
Western Europe 41 976 625  
(38 902 049 to 45 587 058)
5446  
(5069 to 5894)
–5·0%  
(–7·4 to –2·6)
90 450  
(87 105 to 93 977)
7·8  
(7·5 to 8·1)
–0·7%  
(–4·4 to 3·6)
Andorra 6496  
(6040 to 7053)
5243  
(4883 to 5674)
0·8%  
(–3·7 to 5·5)
6  
(5 to 7)
3·6  
(3·1 to 4·2)
–17·9%  
(–30·8 to –3·0)
Austria 857 140  
(791 470 to 932 601)
5557  
(5173 to 6011)
5·3%  
(1·7 to 9·0)
2754  
(2583 to 2939)
12·4  
(11·6 to 13·2)
128·0%  
(111·7 to 145·4)
Belgium 1 101 945  
(1 017 463 to 1 201 817)
5642  
(5238 to 6088)
–1·4%  
(–4·9 to 1·9)
2097  
(1942 to 2265)
7·2  
(6·7 to 7·7)
–29·4%  
(–34·9 to –23·4)
Cyprus 107 744  
(100 226 to 116 301)
6108  
(5693 to 6585)
–6·4%  
(–9·6 to –3·0)
256  
(190 to 288)
13·2  
(9·9 to 14·9)
–23·5%  
(–34·1 to –12·6)
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Denmark 552 944  
(509 440 to 602 169)
5816  
(5400 to 6285)
4·9%  
(1·8 to 8·1)
968  
(903 to 1039)
7·7  
(7·2 to 8·3)
117·1%  
(101·1 to 135·2)
Finland 563 542  
(521 219 to 612 719)
5761  
(5354 to 6220)
–4·5%  
(–8·6 to –0·2)
569  
(528 to 611)
4·0  
(3·7 to 4·3)
18·5%  
(8·9 to 28·5)
France 6 077 964  
(5 589 293 to 6 632 818)
5242  
(4858 to 5697)
–1·7%  
(–6·0 to 2·5)
9279  
(8650 to 10 025)
4·9  
(4·6 to 5·3)
–25·8%  
(–31·8 to –18·7)
Germany 9 046 875  
(8 323 728 to 9 881 743)
5687  
(5256 to 6173)
–4·7%  
(–7·7 to –1·4)
26 754  
(24 215 to 29 510)
11·3  
(10·2 to 12·4)
45·0%  
(30·3 to 61·3)
Greece 1 097 180  
(1 007 649 to 1 203 008)
5342  
(4962 to 5806)
–5·3%  
(–9·1 to –1·1)
3582  
(3333 to 3859)
12·0  
(11·2 to 12·9)
–30·0%  
(–35·3 to –24·1)
Iceland 25 097  
(23 178 to 27 266)
5235  
(4848 to 5703)
0·4%  
(–4·8 to 6·0)
27  
(25 to 29)
4·3  
(4·0 to 4·6)
–1·2%  
(–10·0 to 8·5)
Ireland 394 543  
(365 205 to 426 816)
5985  
(5552 to 6485)
–4·0%  
(–8·4 to 0·7)
579  
(533 to 629)
7·5  
(6·9 to 8·2)
–24·8%  
(–31·8 to –18·1)
Israel 654 367  
(606 819 to 708 940)
6246  
(5810 to 6757)
0·6%  
(–2·1 to 3·3)
2242  
(2088 to 2407)
17·7  
(16·5 to 19·0)
–20·9%  
(–26·6 to –14·2)
Italy 6 163 048  
(5 684 428 to 6 714 537)
5156  
(4792 to 5602)
–9·2%  
(–12·8 to –6·1)
14 292  
(13 318 to 15 333)
7·3  
(6·8 to 7·9)
–19·5%  
(–25·3 to –12·9)
Luxembourg 52 621  
(48 612 to 57 232)
6011  
(5558 to 6548)
–3·3%  
(–7·3 to 0·7)
85  
(76 to 94)
7·7  
(6·9 to 8·6)
–3·7%  
(–14·1 to 7·7)
Malta 45 196  
(41 803 to 49 170)
6053  
(5622 to 6550)
–5·3%  
(–8·6 to –1·7)
94  
(88 to 102)
10·2  
(9·5 to 11·0)
–20·7%  
(–27·6 to –13·6)
Netherlands 1 714 351  
(1 585 981 to 1 860 677)
6142  
(5688 to 6653)
1·3%  
(–3·1 to 6·1)
2683  
(2511 to 2873)
7·1  
(6·7 to 7·6)
6·9%  
(–0·5 to 15·8)
Norway 463 455  
(430 874 to 500 803)
5767  
(5363 to 6220)
10·1%  
(7·2 to 12·8)
590  
(571 to 615)
5·3  
(5·1 to 5·5)
34·5%  
(29·1 to 39·8)
Portugal 1 168 749  
(1 079 819 to 1 269 003)
5817  
(5416 to 6289)
–3·8%  
(–8·4 to 0·8)
3109  
(2876 to 3361)
10·6  
(9·8 to 11·4)
–7·6%  
(–14·7 to 0·3)
Spain 4 233 637  
(3 900 640 to 4 624 353)
5034  
(4647 to 5468)
–5·9%  
(–10·3 to –1·6)
10 605  
(9890 to 11 361)
8·0  
(7·5 to 8·6)
–32·3%  
(–37·5 to –26·5)
Sweden 1 128 448  
(1 048 880 to 1 224 415)
6839  
(6362 to 7400)
3·0%  
(0·3 to 5·7)
1461  
(1370 to 1557)
5·7  
(5·3 to 6·1)
57·5%  
(46·9 to 68·8)
Switzerland 841 113  
(777 449 to 912 670)
5734  
(5321 to 6199)
–1·2%  
(–5·7 to 3·5)
1558  
(1449 to 1676)
7·1  
(6·6 to 7·6)
103·9%  
(87·2 to 122·7)
UK 5 636 676  
(5 233 735 to 6 135 943)
5167  
(4819 to 5589)
–11·4%  
(–13·7 to –8·9)
6766  
(6628 to 6903)
4·5  
(4·4 to 4·6)
–14·5%  
(–16·3 to –12·6)
Southern Latin 
America
5 750 645  
(5 380 566 to 6 189 240)
7402  
(6928 to 7953)
3·9%  
(0·5 to 8·0)
15 847  
(14 763 to 17 075)
18·8  
(17·5 to 20·2)
–7·5%  
(–14·5 to 0·5)
Argentina 3 841 009  
(3 591 989 to 4 123 823)
7547  
(7052 to 8109)
4·1%  
(0·0 to 8·7)
10 834  
(9779 to 11 950)
19·7  
(17·8 to 21·8)
–14·4%  
(–23·0 to –4·7)
Chile 1 569 089  
(1 462 414 to 1 699 444)
7129  
(6657 to 7716)
3·6%  
(0·3 to 7·3)
4225  
(3829 to 4648)
18·1  
(16·4 to 20·0)
26·5%  
(13·7 to 39·6)
Uruguay 340 293  
(315 840 to 369 908)
7112  
(6630 to 7681)
4·5%  
(–0·6 to 10·2)
787  
(713 to 868)
12·9  
(11·6 to 14·2)
–4·2%  
(–14·1 to 6·6)
High-income North 
America
42 289 233  
(39 334 367 to 45 698 132)
7919  
(7403 to 8540)
0·2%  
(–3·5 to 3·9)
91 038  
(89 171 to 92 823)
13·8  
(13·5 to 14·1)
57·3%  
(53·4 to 61·1)
Canada 3 467 822  
(3 213 111 to 3 766 495)
6023  
(5615 to 6523)
5·9%  
(–0·2 to 12·5)
6087  
(5681 to 6544)
7·9  
(7·4 to 8·5)
4·6%  
(–3·5 to 13·6)
Greenland 3965  
(3669 to 4317)
6282  
(5836 to 6806)
–1·8%  
(–5·7 to 2·9)
4  
(3 to 5)
8·3  
(6·0 to 9·2)
12·2%  
(–10·9 to 28·7)
USA 38 816 706  
(36 156 443 to 41 956 816)
8144  
(7615 to 8783)
0·1%  
(–3·6 to 3·8)
84 944  
(83 154 to 86 756)
14·6  
(14·3 to 14·9)
63·0%  
(58·8 to 66·9)
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Caribbean 4 304 951  
(4 005 320 to 4 639 975)
8591  
(8000 to 9263)
3·5%  
(0·1 to 7·6)
11 023  
(10 366 to 11 697)
21·8  
(20·5 to 23·1)
17·2%  
(9·1 to 25·1)
Antigua and Barbuda 9302  
(8632 to 10 029)
9201  
(8552 to 9907)
1·0%  
(–2·5 to 4·9)
26  
(24 to 28)
26·4  
(24·3 to 28·4)
8·3%  
(–2·9 to 18·8)
The Bahamas 35 741  
(33 248 to 38 503)
9207  
(8588 to 9927)
2·2%  
(–1·6 to 6·7)
93  
(85 to 101)
25·9  
(23·7 to 28·1)
14·0%  
(3·1 to 26·3)
Barbados 38 943  
(36 182 to 42 090)
9135  
(8514 to 9833)
3·2%  
(–0·9 to 7·5)
90  
(82 to 97)
18·9  
(17·3 to 20·4)
5·1%  
(–4·7 to 15·5)
Belize 28 612  
(26 651 to 30 832)
9372  
(8720 to 10 097)
8·8%  
(5·3 to 12·8)
84  
(80 to 89)
31·9  
(30·1 to 33·8)
41·5%  
(27·5 to 56·9)
Bermuda 8824  
(8193 to 9609)
8278  
(7730 to 8958)
0·8%  
(–3·4 to 4·9)
16  
(15 to 18)
12·9  
(11·9 to 14·0)
–20·7%  
(–28·3 to –12·0)
Cuba 1 315 812  
(1 215 120 to 1 429 705)
7887  
(7314 to 8545)
1·9%  
(–3·8 to 7·9)
2340  
(2115 to 2584)
12·6  
(11·4 to 14·0)
32·1%  
(19·6 to 47·0)
Dominica 8350  
(7753 to 8987)
9774  
(9081 to 10 542)
5·1%  
(–0·2 to 10·5)
33  
(31 to 36)
35·7  
(33·2 to 38·5)
26·3%  
(15·4 to 38·3)
Dominican Republic 814 154  
(756 845 to 880 779)
8394  
(7804 to 9101)
7·9%  
(3·2 to 13·3)
2308  
(1876 to 2665)
25·0  
(20·2 to 28·9)
74·4%  
(33·9 to 105·5)
Grenada 13 726  
(12 800 to 14 781)
9768  
(9100 to 10 526)
4·5%  
(0·2 to 8·4)
51  
(47 to 54)
32·6  
(30·4 to 34·8)
–0·5%  
(–8·3 to 9·1)
Guyana 63 209  
(58 819 to 68 364)
9689  
(9003 to 10 469)
8·7%  
(4·0 to 14·0)
181  
(159 to 204)
30·1  
(26·7 to 33·9)
39·6%  
(22·5 to 57·3)
Haiti 728 043  
(675 837 to 786 398)
8904  
(8281 to 9634)
–1·9%  
(–5·8 to 2·5)
2083  
(1735 to 2499)
31·5  
(26·4 to 37·5)
–6·3%  
(–22·0 to 11·1)
Jamaica 286 464  
(266 400 to 308 671)
9775  
(9094 to 10 543)
10·6%  
(7·0 to 14·7)
810  
(696 to 929)
27·4  
(23·5 to 31·5)
19·4%  
(0·4 to 39·1)
Puerto Rico 544 395  
(504 959 to 588 309)
9378  
(8726 to 10 113)
3·2%  
(0·2 to 6·5)
1691  
(1581 to 1810)
23·1  
(21·5 to 24·7)
–12·8%  
(–19·5 to –5·6)
Saint Lucia 19 023  
(17 676 to 20 445)
9292  
(8647 to 9980)
–0·7%  
(–4·9 to 3·5)
55  
(51 to 60)
26·8  
(24·5 to 29·0)
–5·6%  
(–14·9 to 3·9)
Saint Vincent and the 
Grenadines
12 863  
(11 964 to 13 872)
9775  
(9106 to 10 535)
6·6%  
(2·9 to 10·7)
37  
(34 to 39)
27·0  
(25·1 to 29·1)
17·4%  
(6·8 to 28·6)
Suriname 55 379  
(51 366 to 59 805)
9464  
(8784 to 10 199)
7·8%  
(3·7 to 11·6)
209  
(188 to 231)
37·7  
(34·0 to 41·5)
37·8%  
(21·8 to 53·9)
Trinidad and Tobago 152 776  
(141 560 to 165 562)
8937  
(8305 to 9664)
3·3%  
(–2·2 to 8·8)
473  
(398 to 559)
27·0  
(22·7 to 31·9)
19·9%  
(0·0 to 42·5)
Virgin Islands 14 527  
(13 404 to 15 773)
9250  
(8597 to 10 011)
5·1%  
(1·1 to 9·7)
48  
(41 to 54)
27·3  
(23·5 to 30·6)
30·1%  
(9·9 to 49·9)
Andean Latin America 4 202 601  
(3 920 607 to 4 538 911)
7473  
(6965 to 8086)
5·1%  
(1·4 to 9·7)
14 191  
(13 149 to 15 259)
26·5  
(24·5 to 28·4)
9·1%  
(–0·2 to 19·8)
Bolivia 713 975  
(665 086 to 772 378)
7663  
(7124 to 8287)
0·9%  
(–3·4 to 4·8)
3165  
(2631 to 3769)
39·7  
(33·1 to 47·1)
3·7%  
(–15·9 to 25·8)
Ecuador 1 207 828  
(1 123 429 to 1 301 635)
7875  
(7333 to 8491)
11·3%  
(6·7 to 16·4)
5739  
(5253 to 6242)
40·2  
(36·8 to 43·8)
95·5%  
(78·0 to 114·0)
Peru 2 280 798  
(2 123 558 to 2 472 702)
7221  
(6710 to 7840)
3·3%  
(–1·9 to 9·1)
5287  
(4609 to 6059)
16·9  
(14·7 to 19·4)
–24·0%  
(–34·2 to –11·4)
Central Latin America 26 908 399  
(25 096 568 to 28 953 310)
11 116  
(10 358 to 11 979)
7·2%  
(4·6 to 10·3)
96 362  
(93 273 to 99 062)
42·1  
(40·8 to 43·3)
60·9%  
(52·7 to 66·2)
Colombia 5 150 794  
(4 775 434 to 5 611 276)
9638  
(8935 to 10 505)
1·1%  
(–4·7 to 6·4)
8502  
(7723 to 9370)
15·7  
(14·2 to 17·3)
–34·1%  
(–40·5 to –26·9)
Costa Rica 505 459  
(468 301 to 546 223)
10 173  
(9441 to 10 974)
5·7%  
(0·7 to 11·5)
1265  
(1173 to 1378)
25·6  
(23·7 to 27·9)
37·5%  
(25·8 to 50·9)
El Salvador 618 749  
(575 374 to 669 028)
10 650  
(9882 to 11 530)
12·4%  
(9·4 to 15·6)
4107  
(2813 to 4846)
71·4  
(48·7 to 84·2)
199·0%  
(46·7 to 270·8)
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Guatemala 1 346 702  
(1 253 013 to 1 449 862)
10 843  
(10 059 to 11 704)
11·9%  
(7·9 to 16·4)
5065  
(4616 to 5545)
47·8  
(43·6 to 52·4)
37·5%  
(24·3 to 52·4)
Honduras 683 978  
(635 326 to 738 666)
10 028  
(9320 to 10 852)
10·4%  
(4·4 to 16·3)
744  
(613 to 886)
13·0  
(10·6 to 15·5)
29·5%  
(4·2 to 57·8)
Mexico 14 556 534  
(13 572 422 to 15 614 239)
12 107  
(11 292 to 13 009)
10·2%  
(7·7 to 13·0)
65 033  
(63 122 to 66 615)
58·1  
(56·4 to 59·5)
102·3%  
(94·4 to 108·8)
Nicaragua 559 208  
(518 841 to 600 857)
10 989  
(10 170 to 11 804)
2·4%  
(–1·0 to 6·1)
2292  
(1959 to 2575)
49·4  
(42·9 to 55·4)
20·9%  
(–6·3 to 39·5)
Panama 396 230  
(367 921 to 428 061)
9979  
(9264 to 10 775)
7·0%  
(2·0 to 12·4)
951  
(889 to 1 019)
23·8  
(22·2 to 25·5)
35·6%  
(24·5 to 47·4)
Venezuela 3 090 745  
(2 860 732 to 3 350 686)
10 502  
(9733 to 11 384)
3·5%  
(–0·4 to 7·7)
8403  
(7418 to 9588)
31·3  
(27·6 to 35·5)
54·9%  
(35·8 to 77·9)
Tropical Latin America 17 263 386  
(16 035 424 to 18 629 836)
7365  
(6842 to 7949)
0·1%  
(–2·5 to 3·1)
36 952  
(36 137 to 37 742)
16·4  
(16·1 to 16·8)
–0·2%  
(–2·7 to 2·2)
Brazil 16 777 334  
(15 579 858 to 18 107 349)
7337  
(6817 to 7918)
–0·2%  
(–2·8 to 2·8)
35 350  
(34 607 to 36 148)
16·1  
(15·8 to 16·5)
–2·1%  
(–4·8 to 0·3)
Paraguay 486 053  
(451 016 to 524 486)
8445  
(7828 to 9144)
11·6%  
(6·7 to 17·0)
1602  
(1287 to 1881)
31·2  
(25·0 to 36·5)
87·3%  
(49·3 to 124·9)
North Africa and Middle 
East
48 796 617  
(45 311 656 to 52 988 276)
10 361  
(9616 to 11 247)
1·9%  
(–1·8 to 5·7)
74 269  
(69 407 to 77 475)
19·7  
(18·4 to 20·6)
–19·6%  
(–24·8 to –14·2)
Afghanistan 1 586 966  
(1 466 363 to 1 730 232)
10 913  
(10 087 to 11 878)
–0·9%  
(–5·3 to 3·3)
3895  
(3305 to 4605)
34·1  
(29·4 to 39·9)
–24·5%  
(–38·5 to 15·2)
Algeria 3 497 207  
(3 232 001 to 3 812 516)
9813  
(9075 to 10 698)
0·9%  
(–3·5 to 5·8)
4577  
(4074 to 5077)
15·6  
(13·8 to 17·2)
–10·6%  
(–20·5 to 0·4)
Bahrain 132 052  
(120 764 to 143 901)
10 427  
(9660 to 11 291)
–1·7%  
(–6·6 to 3·5)
133  
(118 to 148)
22·3  
(19·7 to 24·6)
–42·6%  
(–49·3 to –34·6)
Egypt 7 101 539  
(6 552 681 to 7 720 219)
10 572  
(9754 to 11 521)
5·3%  
(1·4 to 9·6)
13 115  
(11 314 to 14 968)
29·0  
(25·0 to 33·1)
9·4%  
(–5·7 to 25·1)
Iran 8 339 849  
(7 708 434 to 9 055 743)
10 924  
(10 112 to 11 895)
11·3%  
(8·2 to 15·0)
10 163  
(9381 to 10 549)
16·6  
(15·4 to 17·3)
9·8%  
(–0·6 to 17·2)
Iraq 3 044 399  
(2 826 656 to 3 295 432)
10 991  
(10 186 to 11 946)
–9·3%  
(–13·0 to –5·7)
4706  
(4245 to 5123)
21·9  
(19·7 to 23·9)
–60·0%  
(–65·2 to –53·7)
Jordan 745 402  
(691 588 to 808 791)
10 378  
(9635 to 11 277)
–5·0%  
(–8·5 to –1·1)
1281  
(1135 to 1451)
27·5  
(24·5 to 31·0)
–18·0%  
(–30·3 to –3·4)
Kuwait 339 577  
(313 180 to 369 112)
9716  
(8988 to 10 559)
–0·2%  
(–6·0 to 6·3)
177  
(160 to 201)
8·3  
(7·5 to 9·5)
–64·1%  
(–67·7 to –59·6)
Lebanon 668 003  
(618 911 to 726 949)
10 029  
(9284 to 10 928)
–0·3%  
(–5·9 to 5·6)
594  
(533 to 674)
11·2  
(10·0 to 12·6)
–26·6%  
(–37·0 to –13·5)
Libya 594 010  
(548 524 to 644 371)
10 963  
(10 142 to 11 905)
6·6%  
(2·0 to 11·5)
1181  
(1014 to 1363)
29·6  
(25·6 to 33·9)
10·0%  
(–8·4 to 31·5)
Morocco 3 289 444  
(3 046 873 to 3 568 865)
9924  
(9201 to 10 750)
1·5%  
(–3·0 to 6·6)
4544  
(3830 to 5334)
16·3  
(13·9 to 19·1)
6·3%  
(–11·7 to 29·1)
Palestine 307 284  
(283 987 to 333 626)
10 423  
(9590 to 11 333)
–2·2%  
(–5·8 to 1·7)
624  
(580 to 680)
28·5  
(26·3 to 31·2)
–21·5%  
(–33·7 to –6·6)
Oman 324 395  
(297 665 to 352 901)
10 611  
(9836 to 11 554)
9·2%  
(4·2 to 14·9)
253  
(198 to 298)
16·4  
(12·4 to 19·2)
–3·5%  
(–23·1 to 20·0)
Qatar 188 200  
(170 639 to 205 354)
9920  
(9199 to 10 757)
–8·9%  
(–13·3 to –3·6)
115  
(93 to 137)
26·5  
(19·9 to 31·1)
–47·4%  
(–57·7 to –36·0)
Saudi Arabia 2 387 872  
(2 201 128 to 2 595 630)
9892  
(9139 to 10 812)
0·1%  
(–4·0 to 4·4)
3818  
(3111 to 4411)
29·9  
(24·2 to 34·1)
–2·6%  
(–21·7 to 22·7)
Sudan 2 274 010  
(2 106 225 to 2 472 825)
10 107  
(9337 to 11 001)
1·9%  
(–3·2 to 7·3)
3175  
(2662 to 3765)
17·6  
(14·7 to 20·9)
–22·6%  
(–36·1 to –7·7)
Syria 1 384 897  
(1 271 191 to 1 505 808)
9881  
(9099 to 10 748)
–4·8%  
(–8·8 to –0·1)
2257  
(1951 to 2777)
19·7  
(17·1 to 24·9)
–35·0%  
(–44·9 to –21·9)
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Tunisia 1 218 223  
(1 125 849 to 1 331 895)
9916  
(9164 to 10 827)
5·1%  
(–0·6 to 11·9)
1645  
(1358 to 1959)
15·3  
(12·7 to 18·2)
–12·6%  
(–28·3 to 5·7)
Turkey 9 042 506  
(8 350 852 to 9 874 836)
10 311  
(9532 to 11 248)
–2·5%  
(–7·4 to 2·6)
15 153  
(13 383 to 16 778)
17·8  
(15·8 to 19·7)
–32·0%  
(–40·4 to –21·7)
United Arab Emirates 724 351  
(655 751 to 795 089)
9951  
(9198 to 10 828)
–4·0%  
(–7·7 to –0·1)
829  
(648 to 1046)
30·8  
(25·3 to 36·7)
3·0%  
(–18·1 to 29·0)
Yemen 1 560 862  
(1 446 990 to 1 701 455)
9680  
(8964 to 10 522)
1·4%  
(–3·0 to 6·3)
1964  
(1541 to 2463)
16·4  
(13·1 to 20·2)
–19·4%  
(–38·8 to 10·4)
South Asia 143 173 973  
(132 967 984 to 154 589 580)
9470  
(8796 to 10 212)
6·3%  
(3·8 to 9·0)
282 464  
(265 893 to 296 220)
22·8  
(21·2 to 23·9)
–2·6%  
(–12·1 to 6·0)
Bangladesh 11 196 657  
(10 385 604 to 12 137 920)
8300  
(7706 to 9014)
4·0%  
(–0·8 to 8·9)
16 783  
(14 909 to 18 866)
15·4  
(13·7 to 17·3)
–21·8%  
(–38·5 to –6·7)
Bhutan 69 290  
(64 157 to 74 597)
9051  
(8420 to 9756)
2·0%  
(–1·7 to 5·5)
136  
(110 to 162)
23·3  
(18·9 to 27·8)
–24·4%  
(–41·0 to –4·7)
India 115 069 914  
(106 818 767 to 124 130 281)
9529  
(8852 to 10 280)
5·6%  
(3·3 to 8·2)
223 821  
(207 938 to 235 529)
22·3  
(20·6 to 23·5)
–5·5%  
(–14·5 to 2·7)
Nepal 2 174 115  
(2 019 410 to 2 351 912)
9136  
(8487 to 9881)
7·9%  
(3·9 to 12·0)
4879  
(3996 to 5789)
24·2  
(20·0 to 28·6)
–4·0%  
(–21·6 to 16·0)
Pakistan 14 663 997  
(13 591 223 to 15 834 072)
10 162  
(9430 to 10 966)
14·3%  
(10·2 to 18·7)
36 844  
(29 938 to 44 322)
33·9  
(27·8 to 40·6)
42·3%  
(14·2 to 72·9)
Central sub-Saharan 
Africa
6 969 028  
(6 467 179 to 7 541 973)
10 608  
(9846 to 11 488)
0·0%  
(–3·6 to 3·7)
12 587  
(11 086 to 14 024)
28·0  
(24·9 to 31·0)
–17·6%  
(–28·2 to –5·6)
Angola 1 499 658  
(1 389 646 to 1 622 666)
10 592  
(9813 to 11 468)
3·2%  
(–0·7 to 7·6)
2809  
(2395 to 3225)
29·7  
(25·7 to 34·1)
–19·2%  
(–33·0 to 0·1)
Central African Republic 285 293  
(263 420 to 309 434)
10 648  
(9868 to 11 533)
2·1%  
(–1·6 to 6·5)
655  
(535 to 789)
32·9  
(27·4 to 38·5)
–13·9%  
(–27·5 to 4·6)
Congo (Brazzaville) 347 706  
(322 213 to 376 356)
10 938  
(10 170 to 11 826)
–2·9%  
(–6·7 to 0·8)
671  
(552 to 795)
31·4  
(26·3 to 36·2)
–22·5%  
(–36·3 to –7·5)
Democratic Republic of 
the Congo
4 623 446  
(4 286 990 to 5 002 633)
10 558  
(9794 to 11 443)
–0·7%  
(–4·5 to 3·4)
8022  
(6772 to 9290)
26·6  
(22·6 to 30·5)
–17·3%  
(–31·6 to –0·3)
Equatorial Guinea 74 843  
(69 512 to 80 983)
11 174  
(10 350 to 12 064)
0·5%  
(–3·5 to 4·5)
134  
(94 to 185)
32·4  
(23·5 to 43·3)
–30·3%  
(–48·4 to –6·1)
Gabon 138 082  
(128 236 to 149 087)
11 236  
(10 438 to 12 148)
0·9%  
(–3·3 to 4·8)
296  
(252 to 340)
32·4  
(27·9 to 37·0)
–9·6%  
(–22·9 to 5·8)
Eastern sub-Saharan 
Africa
20 233 557  
(18 793 079 to 21 887 248)
9764  
(9054 to 10 549)
1·6%  
(–1·7 to 5·2)
37 332  
(34 896 to 40 455)
25·9  
(24·2 to 28·2)
–27·0%  
(–33·4 to –19·0)
Burundi 535 340  
(495 038 to 579 482)
9648  
(8942 to 10 432)
–5·4%  
(–9·6 to –0·9)
972  
(821 to 1147)
27·1  
(23·3 to 31·4)
–35·0%  
(–45·8 to –23·2)
Comoros 51 396  
(47 609 to 55 653)
9900  
(9159 to 10 708)
–0·9%  
(–5·0 to 3·2)
104  
(89 to 122)
26·3  
(22·6 to 30·6)
–26·9%  
(–39·1 to –12·1)
Djibouti 73 613  
(67 994 to 79 808)
9851  
(9131 to 10 670)
6·6%  
(2·6 to 10·9)
139  
(104 to 182)
30·8  
(23·7 to 38·9)
0·2%  
(–22·4 to 31·3)
Eritrea 304 308  
(282 168 to 329 461)
9868  
(9168 to 10 679)
1·1%  
(–2·8 to 5·5)
641  
(518 to 767)
30·4  
(25·1 to 35·7)
–27·5%  
(–40·9 to –10·6)
Ethiopia 4 968 232  
(4 617 353 to 5 364 731)
9376  
(8694 to 10 139)
–3·9%  
(–7·1 to –0·4)
9083  
(8190 to 10 165)
24·9  
(22·5 to 28·1)
–50·5%  
(–58·0 to –40·7)
Kenya 2 682 885  
(2 489 461 to 2 903 975)
9744  
(9047 to 10 548)
6·5%  
(3·5 to 9·7)
4687  
(4233 to 5204)
25·4  
(22·8 to 28·5)
–2·7%  
(–9·4 to 4·4)
Madagascar 1 333 772  
(1 230 299 to 1 444 892)
9632  
(8917 to 10 446)
3·8%  
(–1·0 to 9·0)
2078  
(1746 to 2424)
22·0  
(18·8 to 25·6)
–19·2%  
(–31·9 to –4·3)
Malawi 982 874  
(912 769 to 1 066 703)
10 371  
(9610 to 11 246)
3·8%  
(–0·2 to 8·8)
1937  
(1686 to 2188)
26·4  
(22·9 to 29·9)
–15·8%  
(–32·0 to 17·9)
Mozambique 1 549 649  
(1 434 294 to 1 673 132)
10 429  
(9689 to 11 261)
4·5%  
(0·6 to 8·8)
2582  
(2177 to 3312)
24·5  
(20·6 to 32·2)
–10·0%  
(–24·8 to 6·6)
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Prevalence (95% UI) Deaths (95% UI)
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
(Continued from previous page)
Rwanda 707 847  
(654 743 to 769 522)
9771  
(9043 to 10 599)
–1·4%  
(–6·3 to 3·7)
1148  
(973 to 1345)
23·7  
(20·3 to 27·6)
–43·0%  
(–52·2 to –32·5)
Somalia 842 140  
(780 582 to 911 025)
10 019  
(9278 to 10 833)
2·2%  
(–1·5 to 5·9)
2023  
(1525 to 2640)
36·0  
(28·1 to 45·2)
–13·7%  
(–34·8 to 20·5)
South Sudan 490 592  
(454 696 to 530 633)
9731  
(9023 to 10 540)
3·9%  
(0·4 to 8·0)
1241  
(965 to 1604)
35·5  
(28·0 to 44·8)
–11·7%  
(–33·8 to 21·2)
Tanzania 2 954 846  
(2 740 477 to 3 216 811)
9737  
(9009 to 10 607)
6·1%  
(1·4 to 10·9)
5806  
(5091 to 6642)
25·3  
(22·2 to 29·0)
–9·9%  
(–23·7 to 10·0)
Uganda 1 854 300  
(1 717 949 to 2 010 440)
10 012  
(9278 to 10 849)
1·1%  
(–3·3 to 5·6)
3015  
(2581 to 3453)
24·4  
(21·1 to 27·7)
–12·7%  
(–28·2 to 3·7)
Zambia 889 069  
(824 745 to 959 071)
10 024  
(9282 to 10 847)
4·7%  
(0·8 to 9·3)
1853  
(1622 to 2099)
31·1  
(27·1 to 35·1)
–25·1%  
(–37·0 to –11·7)
Southern sub-Saharan 
Africa
7 255 813  
(6 732 619 to 7 830 539)
11 615  
(10 808 to 12 512)
10·7%  
(8·0 to 13·5)
12 033  
(11 337 to 12 625)
23·4  
(22·1 to 24·6)
28·7%  
(17·9 to 38·0)
Botswana 196 440  
(182 104 to 211 968)
11 502  
(10 689 to 12 412)
8·6%  
(4·9 to 12·6)
264  
(232 to 306)
22·4  
(19·7 to 25·8)
8·0%  
(–8·0 to 27·1)
eSwatini 88 896  
(82 455 to 95 944)
12 568  
(11 698 to 13 572)
8·8%  
(4·7 to 12·9)
213  
(161 to 258)
39·2  
(30·3 to 47·1)
16·9%  
(–7·1 to 43·9)
Lesotho 166 622  
(154 774 to 180 465)
11 985  
(11 143 to 12 979)
13·3%  
(9·2 to 17·5)
417  
(338 to 501)
36·9  
(30·2 to 43·7)
43·7%  
(15·7 to 75·1)
Namibia 177 623  
(164 822 to 192 771)
10 740  
(9961 to 11 654)
3·1%  
(–1·5 to 8·2)
250  
(215 to 298)
18·9  
(16·3 to 22·5)
–23·4%  
(–33·8 to –10·9)
South Africa 5 681 397  
(5 270 490 to 6 129 994)
11 718  
(10 895 to 12 637)
10·5%  
(7·8 to 13·2)
9149  
(8584 to 9601)
22·3  
(20·9 to 23·4)
28·8%  
(18·0 to 38·5)
Zimbabwe 944 836  
(877 212 to 1 022 937)
11 055  
(10 248 to 11 952)
12·3%  
(8·3 to 16·5)
1740  
(1490 to 2054)
27·9  
(24·1 to 32·6)
47·4%  
(23·9 to 78·6)
Western sub-Saharan 
Africa
26 912 770  
(24 899 147 to 29 243 336)
11 326  
(10 515 to 12 292)
4·3%  
(0·3 to 8·7)
39 718  
(35 515 to 45 758)
20·6  
(18·4 to 23·9)
–24·9%  
(–33·4 to –14·6)
Benin 689 440  
(640 678 to 745 414)
11 194  
(10 368 to 12 149)
1·1%  
(–2·9 to 5·4)
1292  
(1063 to 1553)
26·0  
(21·7 to 31·4)
–21·8%  
(–35·1 to –6·7)
Burkina Faso 1 281 101  
(1 185 130 to 1 383 412)
11 354  
(10 524 to 12 288)
1·8%  
(–2·5 to 6·2)
2769  
(2411 to 3147)
31·9  
(27·8 to 36·2)
–7·9%  
(–21·1 to 9·4)
Cameroon 1 741 850  
(1 622 811 to 1 889 103)
11 370  
(10 591 to 12 359)
2·0%  
(–2·9 to 6·7)
3249  
(2668 to 3 889)
27·9  
(23·0 to 33·5)
–29·7%  
(–42·2 to –16·2)
Cape Verde 55 839  
(51 817 to 60 741)
11 766  
(10 921 to 12 780)
8·6%  
(4·0 to 13·1)
65  
(59 to 72)
13·7  
(12·5 to 15·1)
34·1%  
(12·0 to 54·0)
Chad 779 014  
(723 905 to 844 703)
10 861  
(10 088 to 11 771)
0·1%  
(–4·1 to 4·4)
1568  
(1340 to 1852)
25·0  
(21·2 to 30·0)
–14·8%  
(–27·5 to 0·6)
Côte d’Ivoire 1 642 666  
(1 519 379 to 1 784 152)
11 613  
(10 775 to 12 601)
–0·4%  
(–4·4 to 4·4)
2834  
(2418 to 3404)
26·9  
(23·1 to 32·4)
–19·6%  
(–33·2 to –3·7)
The Gambia 135 988  
(126 031 to 147 163)
11 336  
(10 507 to 12 316)
3·3%  
(–0·7 to 7·2)
243  
(204 to 296)
25·1  
(21·4 to 29·7)
–18·7%  
(–32·3 to –3·5)
Ghana 2 252 649  
(2 090 611 to 2 441 403)
11 483  
(10 673 to 12 422)
7·1%  
(2·6 to 12·0)
3572  
(3055 to 4086)
21·9  
(19·0 to 24·9)
16·7%  
(–4·2 to 38·0)
Guinea 747 095  
(693 302 to 807 476)
11 218  
(10 384 to 12 173)
1·6%  
(–2·7 to 6·2)
1598  
(1392 to 1833)
28·1  
(24·4 to 32·5)
–16·0%  
(–28·0 to –1·5)
Guinea-Bissau 116 129  
(107 475 to 126 088)
11 989  
(11 122 to 12 993)
0·8%  
(–3·3 to 5·5)
260  
(216 to 315)
34·3  
(29·0 to 40·8)
–33·0%  
(–44·8 to –19·5)
Liberia 308 302  
(285 351 to 333 730)
11 511  
(10 683 to 12 463)
0·7%  
(–3·4 to 5·3)
517  
(429 to 627)
25·8  
(21·4 to 31·3)
–29·5%  
(–40·8 to –15·7)
Mali 1 127 953  
(1 044 615 to 1 219 025)
10 783  
(9978 to 11 711)
–2·5%  
(–6·6 to 1·6)
2144  
(1819 to 2546)
22·7  
(19·3 to 27·2)
–36·1%  
(–45·8 to –24·7)
(Table 2 continues on next page)
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and eGFR of 60 mL/min per 1·73 m² or higher, given 
that this population is at the lowest risk for cardiovascular 
disease events.19,21,37–45
Relative risk values for cardiovascular disease outcomes 
were calculated by the Chronic Kidney Disease Prognosis 
Consortium, a research consortium composed of investi-
gators representing several cohorts, including population-
level cohorts with prospective data.21,46–55 Relative risk was 
first calculated within each cohort, then a pooled analysis 
of cohort-level relative risks was done using a random-
effects meta-analysis. Gout relative risk was calculated 
by a random-effects meta-analysis of four studies,56–59 con-
sidering only CKD stages 3–5 indicating increased risk of 
gout.
Exposure, relative risk, and TMREL were used to 
calculate the fraction of fatal and non-fatal burden 
attributable to exposure to impaired kidney function 
(appendix pp 14–15).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Global prevalence
Globally in 2017, there were 697·5 million (95% UI 
649·2 to 752·1) cases of CKD (table 2). Almost a third 
of patients with CKD lived in two countries, China 
(132·3 million [95% UI 121·8 to 143·7] cases) and 
India (115·1 million [106·8 to 124·1] cases). Bangladesh, 
Brazil, Indonesia, Japan, Mexico, Nigeria, Pakistan, 
Russia, the USA, and Vietnam had more than 10 million 
cases of CKD each. 79 of 195 countries included in 
GBD had more than 1 million prevalent cases of CKD in 
2017.
In 2017, the prevalence of CKD was estimated as 
9·1% (95% UI 8·5 to 9·8) in the world’s population, 
with CKD stages 1–2 accounting for 5·0% (4·5 to 5·5), 
stage 3 for 3·9% (3·5 to 4·3), stage 4 for 0·16% 
(0·13 to 0·19), stage 5 for 0·07% (0·06 to 0·08), dialysis for 
0·041% (0·037 to 0·044), and kidney transplantation for 
0·011% (0·010 to 0·012). The age-standardised prevalence 
of CKD was 1·29 (95% UI 1·28 to 1·30) times higher 
in females (9·5% [8·8 to 10·2]) than in males (7·3% 
[6·8 to 7·9]). The global age-standardised incidence of 
dialysis and transplantation was 1·47 (95% UI 1·46 to 1·48) 
times greater among males (13·7 [12·6 to 14·9] per 
100 000 population) than among females (8·6 [7·9 to 9·3] 
per 100 000 population). The global age-standardised CKD 
mortality rate was 1·39 (1·30 to 1·45) times greater among 
males (18·9 [17·9 to 19·5] per 100 000 population) than 
among females (13·6 [13·3 to 14·0] per 100 000 popu-
lation). The country median prevalence of CKD was 8·9% 
(IQR 7·1 to 10·8).
The global age-standardised prevalence of CKD has 
remained stable between 1990 and 2017, with a 1·2% 
(95% UI –1·1 to 3·5) change, although the all-age preva-
lence of CKD has increased by 29·3% (26·4 to 32·6) from 
1990 to 2017. The availability of renal replacement therapy 
from 1990 to 2017 has grown; global all-age incidence 
of dialysis and kidney transplantation increased by 
43·1% (95% UI 40·5 to 45·8) and 34·4% (29·7 to 38·9), 
respectively, while global age-standardised incidence 
rose by 10·7% (9·1 to 12·3) and 12·8% (10·2 to 15·3), 
respectively, with larger increases in all-age incidence of 
Prevalence (95% UI) Deaths (95% UI)
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
Count, 2017 Age-standardised 
rate per 100 000, 
2017
Percentage change in 
age-standardised rates 
between 1990 and 
2017
(Continued from previous page)
Mauritania 271 447  
(251 721 to 294 100)
11 281  
(10 440 to 12 231)
–4·2%  
(–7·9 to 0·1)
460  
(385 to 549)
23·8  
(20·0 to 28·4)
–38·8%  
(–49·5 to –26·8)
Niger 1 047 090  
(970 398 to 1 130 392)
10 774  
(9978 to 11 713)
–1·7%  
(–5·8 to 2·9)
1777  
(1433 to 2203)
21·8  
(17·7 to 27·3)
–35·4%  
(–46·5 to –21·8)
Nigeria 12 681 837  
(11 675 878 to 13 853 971)
11 387  
(10 498 to 12 386)
7·8%  
(1·9 to 14·0)
13 740  
(10 420 to 18 751)
15·0  
(11·3 to 20·6)
–34·1%  
(–50·0 to –11·3)
São Tomé and Príncipe 15 734  
(14 575 to 17 056)
12 188  
(11 288 to 13 210)
0·8%  
(–3·3 to 5·2)
45  
(39 to 52)
44·1  
(38·1 to 50·5)
15·9%  
(–2·5 to 35·8)
Senegal 996 298  
(924 932 to 1 079 051)
11 236  
(10 433 to 12 176)
–0·6%  
(–4·6 to 4·0)
1930  
(1668 to 2282)
27·0  
(23·2 to 32·0)
–27·2%  
(–37·6 to –14·9)
Sierra Leone 510 314  
(472 593 to 552 280)
11 412  
(10 580 to 12 389)
2·0%  
(–1·7 to 6·4)
896  
(775 to 1050)
24·1  
(20·9 to 28·2)
–23·7%  
(–36·8 to –5·9)
Togo 511 758  
(472 213 to 554 594)
11 396  
(10 547 to 12 341)
2·3%  
(–2·0 to 7·2)
759  
(629 to 907)
22·4  
(18·9 to 26·2)
–24·5%  
(–37·6 to –10·2)
UI=uncertainty interval. SDI=Socio-demographic Index.
Table 2: Prevalence and deaths for chronic kidney disease in 2017, and percentage change of age-standardised rates by location, 1990–2017
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renal replacement therapy resulting from population 
ageing. Despite such increases, availability of renal replace-
ment therapy is still limited in many world regions with a 
high burden of CKD.
Global mortality
CKD resulted in 1·2 million (95% UI 1·2 to 1·3) deaths 
in 2017 (table 2). An additional 1·4 million (1·2 to 1·6) 
deaths from cardiovascular disease were attributable to 
impaired kidney function, representing 7·6% (6·5 to 8·8) 
of deaths due to cardiovascular disease in 2017. Deaths due 
to CKD, and cardiovascular disease deaths attributable to 
impaired kidney function, represented 4·6% (95% UI 
4·3 to 5·0) of total mortality. Ranked as the 17th leading 
cause of death in 1990, CKD has increased in impor-
tance, ranking as the 12th leading cause of death in 
2017. The rank of CKD among all causes of death was 
especially prominent in Central and Andean Latin 
America, ranking second and fifth, respectively. The 
global all-age CKD mortality rate increased by 41·5% 
(95% UI 35·2 to 46·5) from 1990 to 2017. The age-
standardised mortality rate remained stable, with a 2·8% 
change (–1·5 to 6·3) from 1990 to 2017. The age-
standardised CKD mortality rate, however, has increased 
by 60·9% (95% UI 52·7 to 66·2) in central Latin America, 
60·9% (53·3 to 68·9) in central Asia, and 57·3% 
(53·4 to 61·1) in high-income North America.
YLDs, YLLs, and DALYs
In 2017, CKD resulted in 7·3 million (95% UI 5·4 to 9·2) 
YLDs, 28·5 million (27·6–29·3) YLLs, and 35·8 million 
Figure 2: Age-standardised rate of DALYs by SDI quintiles for chronic kidney 
disease, 1990–2017
Shaded areas represent 95% uncertainty intervals. DALY=disability-adjusted 
life-year. SDI=Socio-demographic Index.
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Figure 1: Age-standardised rate of DALYs for chronic kidney disease in 2017
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(33·7 to 38·0) DALYs (appendix pp 16–26). Although 
most prevalent cases of CKD are stages 1–2 or stage 3, 
YLDs are largest for CKD stage 5 and dialysis, which 
accounted for 40% and 22% of YLDs for CKD, respectively, 
in 2017. Considerable global variation was noted in CKD 
burden, with age-standardised CKD DALY rates varying 
more than 15-fold between countries (figure 1). American 
Samoa, El Salvador, Federated States of Micronesia, 
Marshall Islands, and Mauritius had the highest esti-
mated rates of age-standardised CKD DALYs in 2017, with 
more than 1500 DALYs per 100 000 population, whereas 
Andorra, Finland, Iceland, and Slovenia had the lowest 
burden, with age-standardised DALYs for CKD of less 
than 120 per 100 000 population. Despite the relatively 
high prevalence of non-fatal CKD, YLDs accounted 
for only 20·3% (95% UI 15·9 to 24·6) of total CKD 
DALYs in 2017, because most of the prevalence of CKD 
was contributed by disease stages 1–2 and stage 3, 
which confer little to no functional health loss. While 
slight increases were estimated in CKD prevalence and 
mortality from 1990 to 2017, global age-standardised rates 
of YLLs and YLDs due to CKD decreased over this period 
by 9·6% (95% UI 5·8 to 13·1) and 4·3% (0·4 to 9·0), 
respectively, thereby resulting in an 8·6% (5·4 to 11·8) 
decrease in the global age-standardised rate of DALYs due 
to CKD.
Burden by SDI
The age-standardised DALY rate due to CKD was highest 
in the low-middle SDI quintile, and was lower in the high 
and high-middle SDI quintiles than in the other quintiles 
in 2017 (appendix pp 26–31). The low SDI quintile saw the 
largest change in age-standardised DALY rates, changing 
by –23·6% (95% UI –29·2 to –16·2) between 1990 and 
2017. The high and middle SDI quintiles saw the smallest 
changes, with age-standardised DALY rates changing 
by –4·0% (–6·5 to –1·8) and –5·5% (–9·3 to –2·3), 
respectively, since 1990 (figure 2). Despite declining age-
standardised DALY rates, all SDI quintiles showed a net 
increase in the absolute number of DALYs attributable 
to CKD from 1990 to 2017, attributable to population 
growth and ageing.
The estimated relation between SDI and expected 
age-standardised rate of CKD DALYs is generally 
negative, with the slope steepening as SDI increases 
(figure 3). Oceania had much higher age-standardised 
DALY rates due to CKD than expected based on SDI for 
all years between 1990 and 2017. Despite gains in SDI over 
time, central Latin America, high-income North America, 
and the Caribbean also saw increasing rates of CKD 
DALYs, by contrast with other world regions. Western, 
eastern, and central sub-Saharan Africa, east Asia, south 
Asia, central and eastern Europe, Australasia, and 
western Europe all had a lower age-standardised CKD 
DALY rate than expected, based on their SDI values.
Causal attribution
CKD due to diabetes accounted for 30·7% (95% UI 
27·8 to 34·0) of CKD DALYs, the largest contribution in 
terms of absolute number of DALYs of any cause in 
2017, with CKD due to type 1 and type 2 diabetes 
resulting in 2·9 million (2·4 to 3·5) DALYs and 
Figure 3: Age-standardised rate of DALYs for chronic kidney disease for 21 world regions, 1990–2017
Solid black line shows expected values across the spectrum of the SDI. DALY=disability-adjusted life-year. SDI=Socio-demographic Index.
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8·1 million (7·1 to 9·2) DALYs, respectively (figure 4A). 
CKD due to other and unspecified causes resulted in 
a substantial number of DALYs across all age groups 
and was estimated to have the highest age-standardised 
rate of DALYs (138·8 [95% UI 123·7 to 155·9] per 
100 000 population) among all causes of CKD. Type 2 
diabetes was the only cause of CKD to show a significant 
increase in the age-standardised DALY rate, which 
changed by 9·5% (95% UI 4·3 to 13·7) from 1990 to 2017 
(figure 4B).
Risk factors for CKD
Impaired fasting plasma glucose, high blood pressure, 
high body-mass index, a diet high in sodium, and lead 
were risk factors for CKD quantified in GBD, accounting 
for 57·6% (95% UI 50·5 to 63·8), 43·2% (42·3 to 54·1), 
26·6% (17·0 to 37·7), 9·5% (3·7 to 18·0), and 3·6% 
(2·3 to 5·1), respectively, of the age-standardised rate of 
CKD DALYs in 2017. High blood pressure accounted for 
the largest proportion of CKD burden in east Asia, 
eastern Europe, tropical Latin America, and western 
sub-Saharan Africa, whereas high fasting plasma glucose 
was the leading risk factor for CKD in all other regions.
Impaired kidney function as a risk factor
In 2017, impaired kidney function resulted in 61·3 mil-
lion (95% UI 56·9 to 66·1) DALYs, of which 58·4% 
(55·4 to 61·4) were directly contributed by CKD whereas 
41·6% (38·2 to 44·4) were cardiovascular disease DALYs 
and less than 1% (0·003% [95% UI 0·002 to 0·004]) were 
gout DALYs attributable to impaired kidney function, 
although the composition was different by world region 
(figure 5). Of 25·3 million (95% UI 22·2 to 28·9) 
DALYs resulting from cardiovascular disease attributable 
to impaired kidney function, 58·8% (54·0 to 63·7) 
came from ischaemic heart disease, 40·2% (35·4 to 45·0) 
from stroke, and the remaining 1·0% (0·6 to 1·5) from 
peripheral artery disease. The global age-standardised 
rate of cardiovascular disease DALYs attributable to 
impaired kidney function in 2017 was 318·3 (278·9 to 
363·2) DALYs per 100 000 population. With an age-
standardised rate of 1028·4 (866·0 to 1218·8) DALYs 
per 100 000 population, Oceania had the largest age-
standardised rate of cardio vascular disease DALYs 
attributable to impaired kidney function, followed by 
central Asia, eastern Europe, and north Africa and the 
Middle East, which all had age-standardised DALY rates 
Figure 4: Number (A) and rate (B) of global DALYs for CKD by underlying cause in 1990 and 2017
DALY=disability-adjusted life-year. CKD=chronic kidney disease.
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above 500 per 100 000 population. Since 1990, the age-
standardised rate of cardiovascular disease DALYs due to 
impaired kidney function has decreased globally by 
29·4% (95% UI 26·4 to 32·2), although central Asia saw 
a rise of 10·5% (4·9 to 16·3).
Information on input data sources for cause of death, 
non-fatal, and risk factor models can be downloaded 
from the Global Health Data Exchange.60 Complete GBD 
2017 results are available online for visualisation and can 
be downloaded from the Global Health Data Exchange.61
Discussion
The number of individuals with all-stage CKD reached 
almost 700 million in 2017, which is more people than 
those with diabetes, osteoarthritis, chronic obstructive 
pulmonary disease (COPD), asthma, or depressive disor-
ders.26 CKD diagnoses resulted in 1·2 million deaths in 
2017, a number that has been projected to rise by 2040 to 
2·2 million in a best-case scenario and up to 4·0 million 
in a worst-case scenario.62 GBD ranks CKD as the 
12th leading cause of death out of 133 conditions.28 
Globally in 2017, CKD resulted in more deaths than did 
tuberculosis or HIV, and the number of CKD deaths was 
almost equal to the number of deaths due to road 
injuries.27 The decrease in the global age-standardised 
DALY rate for CKD from 1990 to 2017 was not accom-
panied by corresponding decreases in age-standardised 
rates of CKD mortality or prevalence, indicating a shift 
to mortality due to CKD occurring at an older age and 
lower average severity of non-fatal CKD. However, these 
declines are slower than for cardiovascular disease and 
stroke. A handful of locations deviated from this global 
trend and had a greater than 50% increase in the age-
standardised CKD DALY rate from 1990 to 2017, including 
American Samoa, Ecuador, El Salvador, Georgia, Guam, 
Mexico, Paraguay, and Philippines. The increases in CKD 
burden in these locations have been largely driven by 
substantial increases in the CKD mortality rate. Although 
there is still uncertainty about the cause of CKD in some 
populations with high CKD mortality,63 studies from 
American Samoa,64,65 Guam,64 and Mexico66,67 suggest that 
limited access to renal replacement therapy combined 
with increases in the prevalence of diabetes and hyper-
tension have contributed to rising CKD burden in these 
regions. We found a higher prevalence of CKD stages 1–3 
in females and higher mortality in males, which suggests 
that males progress to ESKD more rapidly. There is 
evidence of substantial gender disparities in access to 
CKD treatment, and actions are needed to provide equal 
access to kidney health care.68,69 These results highlight 
the importance of improved manage ment of risk factors 
for CKD at primary care level and the need for expanded 
access to affordable renal replacement services for those 
with ESKD.
We have not seen the same degree of progress in 
prevention of CKD mortality as we have for many other 
important non-communicable diseases. From 1990 to 
2017, the global age-standardised mortality rate declined 
Figure 5: Age-standardised rate of DALYs for chronic kidney disease, cardiovascular diseases, and gout, attributable to impaired kidney function, for 21 world 
regions in 2017
DALY=disability-adjusted life-year.
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by 30·4% for cardiovascular disease, 14·9% for cancer, 
and 41·3% for COPD,27 but a similar decline was not seen 
for CKD (2·8% change [95% UI –1·5 to 6·3]). Disparities 
in CKD mortality by world region highlight the import-
ance of access to renal replacement therapy, both to 
initiate treatment and to maintain access to dialysis. 
For instance, in sub-Saharan Africa, even if individuals 
requiring renal replacement initiate treatment, retention 
is low because of an inability to pay for ongoing dialysis, 
and up to 85% of incident patients are forced to withdraw 
from this life-saving treatment.70 Public health policy also 
has a role in slowing the incidence rate of ESKD through 
education of health personnel, early kidney disease 
detection programmes and implementation of nephro-
protective treatment, and appropriate treatment of CKD 
risk factors such as high systolic blood pressure and 
elevated glucose levels.15 This action could be especially 
important in low SDI regions where primary care health 
systems are focused on child and maternal health and are 
less equipped to adequately prevent and treat chronic 
diseases.71 In view of the detrimental interplay between 
diabetes, hypertension, CKD, and development of cardio-
vascular disease, one alternative could be to integrate 
screening of CKD in ongoing efforts to reduce the 
occurrence of cardiovascular disease. Studies suggest that 
screening for CKD in high-risk and elderly populations 
is a cost-effective approach to reduce progression to 
ESKD and CKD mortality.72–75 The effect of kidney disease 
on the burden of non-communicable diseases is not 
limited to ESKD or CKD itself but extends to cardio-
vascular diseases for which impaired kidney function is 
an independent risk factor.19,22 According to our analysis, 
almost 7% of the total cardiovascular disease burden can 
be attributed to impaired kidney function. Of all the 
global risk factors in 2017, the DALY rate for impaired 
kidney function was higher than that for drug use, unsafe 
sanitation, low physical activity, second-hand smoke, and 
several dietary risk factors.29 However, kidney health is 
given far less attention than the aforementioned risk 
factors, both by public health authorities and the general 
population. Fewer than 10% of patients with CKD are 
aware of their disease, both in developing14 and developed76 
countries. According to the Global Kidney Health Atlas 
2017, CKD is recognised as a health-care priority in 36% 
of countries, a national strategy for combating all stages 
of CKD is available in 17% of countries, and awareness 
and adoption of CKD guidelines among primary and 
secondary care specialists is estimated to be below average 
in 49% of countries.
Kidney care is closely related to global health 
challenges. The gap between age-standardised CKD 
DALY rates in low, low-middle, and middle SDI quintiles 
compared with high and high-middle SDI quintiles 
reflects inequities in access to preventive care and renal 
replacement therapy across levels of development. The 
low SDI quintile saw the largest decrease in age-
standardised CKD DALY rates from 1990 to 2017, 
primarily as a result of substantial decreases in the age-
standardised mortality rate in many countries in the low 
SDI quintile, including Ethiopia, Niger, and Rwanda. 
Nevertheless, the fraction of all deaths in these countries 
attributable to CKD has steadily increased over the past 
20 years, indicating that differences in CKD burden 
observed between low-middle and low SDI quintiles 
might diminish when overall declines in all-cause 
mortality rate slow, particularly as exposures to risk 
factors for CKD, including diabetes, hyper tension, and 
high body-mass index, continue to amplify in the low 
SDI quintile. For these countries at the lower end of the 
development spectrum, the situation has been aggravated 
by insufficient access to laboratory diagnostic services,77 a 
shortage of medical personnel,78 scarce medi cation, and 
the absence of universal health coverage.79 Disparities in 
access to CKD care also exist within countries for 
different populations, some of which are at higher risk of 
late referral to nephrology services,80 resulting in greater 
rates of complications and mortality.81
The prevalence of CKD reported in GBD 2017 
(9·1% [95% UI 8·5 to 9·8]) is lower than the global 
prevalence estimate from a meta-analysis published in 
2016 (13·4%).82 This difference is attributable to variations 
in methodological approach and data inclusion criteria. 
For the estimation of CKD prevalence, GBD excluded 
studies reporting on clinic-based or laboratory-based 
populations, because patients with creatinine samples 
for CKD in these instances tend to belong to high-
risk groups, leading to overestimation of CKD prevalence. 
Moreover, GBD also accounted for differences in age and 
sex distributions across input data sources, thus ensuring 
that data affected prevalence estimates only for the 
demographic subset from which they were gathered. 
Estimates of CKD prevalence in GBD 2017 are higher 
than those reported in previous iterations of GBD, 
primarily because of inclusion of CKD stages 1–2 as part 
of the GBD definition of CKD for GBD 2017.
Several limitations applicable to GBD have been 
discussed in detail elsewhere.26–29 Limitations specific to 
CKD apply to the current analysis.
First, many countries do not have high-quality 
population-based studies on the occurrence of CKD. 
Some regions with the highest burden of CKD (eg, 
Central America, Latin America, and Oceania) have little 
to no available data for CKD incidence or prevalence 
within the population (appendix p 7); as such, GBD must 
rely on statistical methods and predictive covariate values 
to estimate CKD burden in these regions. Additionally, 
despite the standardised definition of CKD presented 
by the KDIGO guidelines,22 sources of information on 
non-fatal CKD vary in terms of sampling, laboratory 
methods, and the equation used to calculate eGFR. 
Several studies have noted systematic differences in 
estimated CKD prevalence resulting from the use of 
different equations.46,83–88 To account for these differences 
and standardise data across studies, we adjusted data 
For the Global Kidney Health 
Atlas 2017 see https://www.
theisn.org/focus/ckd#health-atlas 
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sources to represent prevalence as calculated according 
to our reference definition of eGFR, estimated using 
the CKD-EPI equation.32 This correction increases the 
uncertainty of input data and was derived from a limited 
number of sources, which might not accurately charac-
terise bias within different demographic subsets of the 
population. Future iterations of GBD should expand the 
number of sources used for this analysis to evaluate if 
these adjustment factors vary by sex, age, ethnicity, or 
geographical location.
Second, most data sources reporting the prevalence 
of non-fatal CKD are cross-sectional and do not repeat 
serum creatinine and urine ACR measurements over 
3 months, as suggested by KDIGO guidelines, to confirm 
the chronicity of abnormalities.22 Studies suggest that use 
of one measurement of decreased eGFR to characterise 
CKD might overestimate prevalence by 25–50%.89–92 
Therefore, it is possible that the results of our analysis 
represent an overestimate of CKD prevalence. Future 
analyses of the global burden of CKD should investigate 
developing a methodology to correct prevalence estimates 
based on one eGFR measurement, as done to correct for 
differences in prevalence estimates resulting from use of 
alternate estimating equations.
Third, ascertainment of the cause of CKD is difficult. 
Biopsy is the gold-standard method for assigning the 
underlying cause of CKD, but this procedure is only 
advised when confirmation of cause is necessary and the 
benefits of confirmation outweigh risks of the procedure. 
Additionally, CKD often arises from comorbid conditions, 
contributing to a large degree of uncertainty about the 
true underlying cause of CKD. To capture this uncertainty 
and better reflect clinical realities of causal attribution, 
we used data from the Geisinger Health System35 to 
identify patients with various stages of CKD, relying on 
ICD codes for primary renal diseases to map individuals 
to GBD cause groupings and assigning individuals with 
CKD but no ICD code for a primary renal disease as 
having CKD of unknown cause. This method marks an 
improvement over previous iterations of GBD in which 
the distribution of CKD by cause was generated using 
data solely from renal replacement therapy registries and 
was assumed to be the same across all stages. However, 
the generalisability of Geisinger data to CKD populations 
worldwide is limited, because there is considerable 
geographical variation in the distribution of primary 
renal diseases. Use of clinical data also probably 
represents a skewed causal distribution in early-stage 
CKD, because many cases of mild kidney function 
decline are asymptomatic, so there could be differential 
case-ascertainment based on primary renal disease.
Fourth, impaired kidney function as defined for GBD 
risk factor estimation does not explicitly quantify the risk 
of elevated ACR and decreased eGFR separately, despite 
evidence that elevated ACR leads to increased risk for 
cardiovascular outcomes independent of decreased 
eGFR.93 Estimation of attributable burden separately 
by ACR and eGFR would provide additional insights for 
treatment and prevention of cardiovascular disease 
outcomes among individuals with impaired kidney 
function. We also only quantified the burden of 
cardiovascular disease and gout attributable to impaired 
kidney function; however, impaired kidney function 
might also put individuals at risk for other outcomes that 
we have not yet accounted for. Additional outcomes for 
impaired kidney function could be added to future GBD 
iterations if evidence can establish a causal link.
Finally, the GBD estimation framework for CKD does 
not currently estimate anaemia impairment for cases of 
ESKD on dialysis or ESKD after transplant. Patients on 
dialysis have a high prevalence of anaemia, the severity 
of which could affect the level of disability they experi-
ence. The disability weight associated with dialysis is 
relatively high; however, the lay description associated 
with this health state also includes symptoms asso ci-
ated with anaemia. Nevertheless, this might have 
resulted in an underestimate of the disability associated 
with dialysis.
In conclusion, CKD is a highly prevalent condition that 
contributes a substantial proportion of disease burden 
glo bally, yet over the past 27 years the burden of CKD has 
not declined to the same extent as many other important 
non-communicable diseases. The age-standardised effect 
of CKD is more prominent in countries in low and 
middle SDI quintiles, where there is a large gap between 
CKD burden and provision of adequate health care. 
Importantly, slowing CKD progression at early stages 
provides economic benefits94 and prevents the develop-
ment of ESKD and cardiovascular complications.22 
A comprehensive action plan should include effective 
management of risk factors for CKD at the primary care 
level, improved case-detection among at-risk populations, 
and development of facilities for treating patients with 
documented disease. By jointly implementing CKD 
prevention, assessment, and treatment, we could achieve 
better health for many populations with a high burden 
of CKD and related outcomes. The UN Sustainable 
Development Goals aim to reduce premature mortality 
from non-communicable diseases by a third by 2030. 
Our estimates suggest that targeting CKD could be an 
important step in reaching these goals.
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